Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poly(ADP-ribose) Polymerase Inhibitors”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Testing effectiveness (Phase 2)Looking for participantsNCT05894018
What this trial is testing

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

Who this might be right for
Sarcoma,Soft TissueBrachytherapyPoly(ADP-ribose) Polymerase Inhibitors
Fujun Zhang 32
Early research (Phase 1)Study completedNCT03150810
What this trial is testing

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
BeiGene 139
Not applicableLooking for participantsNCT06785077
What this trial is testing

Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors

Who this might be right for
Leukemia, Myeloid, AcuteMyeloid DysplasiaOvarian Epithelial Cancer
European Institute of Oncology 157
Very early researchUnknownNCT02469129
What this trial is testing

PET Imaging of PARP Activity in Cancer

Who this might be right for
Cancer
Washington University School of Medicine 50
Testing effectiveness (Phase 2)UnknownNCT03951415
What this trial is testing

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer

Who this might be right for
Endometrial NeoplasmsUterine NeoplasmsEndometrium Cancer
Leiden University Medical Center 55
Testing effectiveness (Phase 2)Ended earlyNCT04538378
What this trial is testing

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Who this might be right for
EGFR-Mutated Non-Small-Cell Lung CarcinomaSmall Cell/Neuroendocrine
National Cancer Institute (NCI) 4
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Not applicableApproved For MarketingNCT03079687
What this trial is testing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Who this might be right for
Ovarian Cancer
AstraZeneca
Not applicableUnknownNCT05310370
What this trial is testing

HRD and Resistance to PAPPi in EOC Patients

Who this might be right for
Epithelial Ovarian CancerHomologous Recombination DeficiencyHomologous Recombination Repair Gene Mutation+4 more
Lei Li 400
Not applicableStudy completedNCT04785716
What this trial is testing

Real-life Use of Niraparib in a Patient Access Program in Norway

Who this might be right for
Ovarian CancerPeritoneal Cancer
Kristina Lindemann 106
Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41
Testing effectiveness (Phase 2)Study completedNCT03150862
What this trial is testing

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Who this might be right for
Brain and Central Nervous System Tumors
BeiGene USA, Inc. 116